Key points are not available for this paper at this time.
Introduction p=0.25) or duration of CGM use (r=-0.03; p=0.15). The problematic SHE cohort reported slightly longer T1D duration (M=31.9 years) than other cohorts (M=26.8-28.6 years). Conclusion: Severe hypoglycemia remains an important clinical risk for adults with T1D regardless of time spent living with T1D or duration of advanced monitoring technology use. Disclosure A. Boateng-Kuffour: Employee; Vertex Pharmaceuticals Incorporated. P. Callahan: Employee; Vertex Pharmaceuticals Incorporated. K. Chandarana: Employee; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Vertex Pharmaceuticals Incorporated, Novo Nordisk, Eli Lilly and Company. D. Barry: Employee; Vertex Pharmaceuticals Incorporated. L. Chen: None. C.S. Kelly: None. H. Nguyen: None. K.S.M. Chapman: None. E.M. Cornelius: None. W. Wolf: None. W.H. Polonsky: Research Support; Abbott Diagnostics, Dexcom, Inc. Consultant; Eli Lilly and Company, Sanofi. Advisory Panel; embecta. Consultant; Vertex Pharmaceuticals Incorporated. Advisory Panel; 9am Health. Funding Vertex Pharmaceuticals Incorporated
Boateng-Kuffour et al. (Fri,) studied this question.